Cargando…

Sevelamer reduces endothelial inflammatory response to advanced glycation end products

BACKGROUND: Advanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum in vitro and then test this pharmace...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gregório, Paulo C, Favretto, Giane, Sassaki, Guilherme L, Cunha, Regiane S, Becker-Finco, Alessandra, Pecoits-Filho, Roberto, Souza, Wesley M, Barreto, Fellype C, Stinghen, Andréa E M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	CKD Complications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798142/ https://www.ncbi.nlm.nih.gov/pubmed/29423208 http://dx.doi.org/10.1093/ckj/sfx074

Ejemplares similares

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study
por: Stack, Austin G, et al.
Publicado: (2018)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

CKD-MBD KDIGO guidelines: how difficult is reaching the ‘target’?
por: Cozzolino, Mario
Publicado: (2018)

Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study
por: Fouque, Denis, et al.
Publicado: (2018)

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
por: Bouma-de Krijger, Annet, et al.
Publicado: (2019)

Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease
por: van der Vorm, Lisa N, et al.
Publicado: (2019)

Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease
por: Hunt, Taylor V, et al.
Publicado: (2018)

Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets
por: Favretto, Giane, et al.
Publicado: (2019)

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
por: Soro-Paavonen, Aino, et al.
Publicado: (2008)

Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy
por: Brown, Stephanie A, et al.
Publicado: (2017)

Frailty and chronic kidney disease: current evidence and continuing uncertainties
por: Nixon, Andrew C, et al.
Publicado: (2018)

Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 Mouse
por: Reiniger, Nina, et al.
Publicado: (2010)

Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes
por: Saulnier, Pierre-Jean, et al.
Publicado: (2016)

Renal artery intervention utilizing carbon dioxide angiography
por: Sag, Alan A, et al.
Publicado: (2017)

Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease
por: Hameed, Mohammed Awais, et al.
Publicado: (2017)

Patterns of progression of chronic kidney disease at later stages
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2018)

The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker
por: Canney, Mark, et al.
Publicado: (2018)

A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records
por: Friberg, Leif, et al.
Publicado: (2018)

Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2017)

The metabolomic quest for a biomarker in chronic kidney disease
por: Davies, Robert
Publicado: (2018)

The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary
por: Pippias, Maria, et al.
Publicado: (2017)

Current trends in European renal epidemiology
por: Heaf, James
Publicado: (2017)

Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2017)

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis
por: Iyasere, Osasuyi, et al.
Publicado: (2018)

Clarifying the concept of chronic kidney disease for non-nephrologists
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Impact of a phone app on nephrology referral
por: Oliva-Damaso, Nestor, et al.
Publicado: (2018)

Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients
por: Lai, Silvia, et al.
Publicado: (2018)

Anticoagulant-related nephropathy: systematic review and meta-analysis
por: de Aquino Moura, Karolinny Borinelli, et al.
Publicado: (2019)

Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1
por: Barbieri, Diego, et al.
Publicado: (2018)

Is polypharmacy an increasing burden in chronic kidney disease? The German experience
por: Parker, Kathrine, et al.
Publicado: (2019)

Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study
por: Schmidt, Insa M, et al.
Publicado: (2019)

Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care
por: Lefebvre, Claire, et al.
Publicado: (2019)

Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes
por: Genuth, Saul, et al.
Publicado: (2015)

Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes
por: Selvin, Elizabeth, et al.
Publicado: (2011)

Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs)
por: Rempel, Lisienny C. T., et al.
Publicado: (2015)

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial
por: Colhoun, Helen M., et al.
Publicado: (2011)

Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes
por: Lopes-Virella, Maria F., et al.
Publicado: (2011)

In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients
por: Gregório, Paulo C., et al.
Publicado: (2021)

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study
por: Nin, Johanna W.M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rchf24c579i3q8h72ij0fh1vq9